March 29, 2007 -- CuraGen sold its majority-owned 454 Life Sciences division to Roche for $155 million; NeoPharm said the FDA will require another clinical trial before approving its drug for brain cancer; Enzon began treating patients in a Phase I trial of a new cancer drug; Alnylam Pharma sold a non-exclusive license for RNAi research products to Bio-Rad; Baxter released positive Phase I/II data for its avian flu vaccine and began Phase III tests; Targeted Genetics gained 66% on a positive Q4 report; Pain Therapeutics will buy back $20 million of its stock; Hollis-Eden filed an IND for a metabolic disorders drug; and Avanir will restructure its operations to focus on approval of Zenvia, its treatment for diabetic neuropathy. The Centient Biotech 200™ climbed 12 points to 3863, a rise of .33%. More details...
